

Dr. ROSENOW. We do not restrict—we do not ordinarily take pharmaceutical ads, investments, but we do not say that we cannot. I would say at the moment that we do not have any, but I am not absolutely sure. We had Smith Kline & French a few years ago, but we do not have that any more. We do not have a policy against it. This is run by an investment company we work with, Drexel, Harriman & Ripley Investment Counselors. We are a little bit touchy about tobacco investments; we do not take those. But we have no firm rule against it. So that essentially I would say that we would have to be a little extra persuaded that a pharmaceutical company was a good investment for our college.

Senator NELSON. If you have an investment in pharmaceuticals now, would you notify the committee as to what they are?

Dr. ROSENOW. Yes.

Dr. POLLARD. I believe it is true that there are none in pharmaceutical houses at the present time.

Senator NELSON. Thank you.

Dr. ROSENOW. You asked the total amount of our investment account.

Senator NELSON. Yes.

Dr. ROSENOW. I would also have to furnish this. But I think at its mark value it is somewhere around \$3 or \$3½ million.

Senator NELSON. Please go ahead.

Dr. POLLARD. Because of increased activities, additional office space is required. We are in the planning stages of plant expansion which could cost up to \$1 million. The funds to pay for this addition must come from the sources mentioned above.

A committee on diagnostic and therapeutic agents has been appointed recently under the chairmanship of Dr. Carter Smith, of Atlanta, Ga. They plan a continuing study of all aspects of these agents. Although no specific policy statements have been developed on some of the matters of concern to your committee, such policy statements will be forthcoming from time to time. However, the following general comments I believe fairly represent what would reflect the attitudes of a majority of our members:

COMPENDIUM

Physicians must have accurate, up-to-date information about drugs. A number of methods are helpful in this regard. Physicians' Desk Reference is a convenient source of information about the drugs included, but is incomplete. The objection raised that there is no editorial review of what goes into PDR has been corrected by requiring that the FDA-approved package insert information be included.

Senator NELSON. The FDA doesn't require the PDR to print the whole package insert. I think it requires that it conform to it, however.

Dr. ROSENOW. That is right. But PDR has adopted, I believe, that they put in the product insert as their writeup.

Senator NELSON. In toto?

Dr. ROSENOW. I believe so.

Senator NELSON. I did not realize that.

Dr. POLLARD. That is essentially what the PDR is.

Senator NELSON. From some that I have looked at in the past, it was